The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 19, 2019
Filed:
Feb. 24, 2017
Applicant:
The Trustees of Columbia University IN the City of New York, New York, NY (US);
Inventors:
Brent R. Stockwell, New York, NY (US);
Scott J. Dixon, New York, NY (US);
Rachid Skouta, New York, NY (US);
Assignee:
Other;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 213/74 (2006.01); A61K 31/47 (2006.01); C07D 401/12 (2006.01); C07D 309/14 (2006.01); C07C 255/58 (2006.01); C07D 213/80 (2006.01); C07C 271/16 (2006.01); C07C 271/24 (2006.01); C07C 271/28 (2006.01); C07C 205/57 (2006.01); C07C 205/58 (2006.01); C07C 211/50 (2006.01); C07D 239/26 (2006.01); C07C 229/60 (2006.01); C07C 233/54 (2006.01); C07C 237/30 (2006.01); C07D 295/088 (2006.01); C07D 211/58 (2006.01); C07D 295/30 (2006.01); C07D 213/36 (2006.01); A61K 31/245 (2006.01); A61K 31/325 (2006.01); A61K 31/351 (2006.01); A61K 31/4465 (2006.01); A61K 31/495 (2006.01); A61K 31/5375 (2006.01); A61K 45/06 (2006.01); C07C 69/78 (2006.01); C07D 295/192 (2006.01); A61K 31/27 (2006.01); A61K 31/44 (2006.01); A61K 31/444 (2006.01); A61K 31/4468 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); C07C 225/22 (2006.01); C07D 239/42 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/245 (2013.01); A61K 31/27 (2013.01); A61K 31/325 (2013.01); A61K 31/351 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4465 (2013.01); A61K 31/4468 (2013.01); A61K 31/495 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5375 (2013.01); A61K 45/06 (2013.01); C07C 69/78 (2013.01); C07C 205/57 (2013.01); C07C 205/58 (2013.01); C07C 211/50 (2013.01); C07C 225/22 (2013.01); C07C 229/60 (2013.01); C07C 233/54 (2013.01); C07C 237/30 (2013.01); C07C 255/58 (2013.01); C07C 271/16 (2013.01); C07C 271/24 (2013.01); C07C 271/28 (2013.01); C07D 211/58 (2013.01); C07D 213/36 (2013.01); C07D 213/74 (2013.01); C07D 213/80 (2013.01); C07D 239/26 (2013.01); C07D 239/42 (2013.01); C07D 295/088 (2013.01); C07D 295/192 (2013.01); C07D 295/30 (2013.01); C07D 309/14 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2601/18 (2017.05); C07C 2601/20 (2017.05); C07C 2603/74 (2017.05);
Abstract
The present invention provides, inter alia, a compound having the structure: Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.